Seeking Alpha

Idenix Pharmaceuticals (IDIX +16.6%) moves up today after being initiated with a Buy at Deutsche...

Idenix Pharmaceuticals (IDIX +16.6%) moves up today after being initiated with a Buy at Deutsche Bank. The firm says the Street is undervaluing IDIX's new drug pipeline, as investors have been spooked since the FDA put a clinical trials of its lead hepatitis C candidate on hold in August. IDIX recently said study data showed the drug is safe and cured 82% of patients, and the agency's decision on lifting the hold - expected early 2013 - is the key event for the stock.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|